A randomized trial tested tenecteplase in patients with acute central retinal artery occlusion (CRAO) with a best-corrected visual acuity (BCVA) ≤0.1 (≥1.0 logMAR) who were treated within 4.5 hours of symptom onset[7]. It compared tenecteplase 0.25 mg/kg plus placebo with acetylsalicylic acid 300 mg plus placebo in a multicenter, double-blind design[4][5]. The primary endpoint was the percentage of patients with BCVA ≤0.7 logMAR (≥0.2 decimal or ≥6/30 fractional) at day 30, representing a clinically meaningful improvement of ≥0.3 logMAR (15 letters)[ 4 ]. Secondary outcomes included BCVA ≤0.5 logMAR (≥0.32 decimal or ≥6/19 fractional), quality of life, modified Rankin score at 30 and 90 days, and safety including symptomatic intracranial hemorrhage, major hemorrhage, and mortality[4][5]. The study was published in the New England Journal of Medicine (Vol. 394, No. 5, pp. 442-450, January 29, 2026)[7]. The main findings are not detailed in the available sources, it is a randomized trial of tenecteplase in CRAO[7].